ANI Gross Profit from 2010 to 2025

ANIP Stock

USD 55.01 0.50 0.92%

ANI Pharmaceuticals Gross Profit yearly trend continues to be relatively stable with very little volatility. Gross Profit is likely to grow to about 368.7 M this year. Gross Profit is the profit ANI Pharmaceuticals makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2000-03-31

Previous Quarter

65.6 M

Current Value

85.3 M

Quarterly Volatility

21.8 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 72.2 M, Interest Expense of 32.5 M or Selling General Administrative of 181.6 M, as well as many indicators such as Price To Sales Ratio of 2.23, Dividend Yield of 0.0012 or PTB Ratio of 2.37. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of ANI Pharmaceuticals Correlation against competitors.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Latest ANI Pharmaceuticals' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of ANI Pharmaceuticals over the last few years. Gross profit is a required income statement account that reflects total revenue of ANI Pharmaceuticals minus its cost of goods sold. It is profit before ANI Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. ANI Pharmaceuticals' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 332.11 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

ANI Gross Profit Regression Statistics

	Arithmetic Mean	125,685,799
	Coefficient Of Variation	96.08
	Mean Deviation	90,060,629
	Median	115,526,000
	Standard Deviation	120,761,422
	Sample Variance	14583.3T
	Range	375.5M
	R-Value	0.92
	Mean Square Error	2271T
	R-Squared	0.85
	Slope	23,449,346
	Total Sum of Squares	218749.8T

ANI Gross Profit History

	2025	368.7 M
	2024	351.1 M
	2023	305.3 M
	2022	177.6 M
	2021	115.5 M
	2020	121.3 M
	2019	143.4 M

Other Fundumenentals of ANI Pharmaceuticals

Gross Profit Margin

ANI Pharmaceuticals Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Long Term Debt	Good Will	Long Term Debt Total	Long Term Investments	Treasury Stock	Intangible Assets	Property Plant Equipment	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Accumulated Depreciation
Total Assets		0.99	0.5	0.12	0.96	0.99	0.96	-0.46	-0.25	0.67	0.98	0.17	0.97	0.93	0.67	0.65	-0.8	0.78	0.91	0.88	-0.8	0.84	0.86	0.9	-0.77
Total Stockholder Equity	0.99		0.41	0.09	0.96	0.98	0.98	-0.44	-0.22	0.7	0.96	0.22	0.96	0.93	0.65	0.69	-0.75	0.73	0.87	0.86	-0.76	0.85	0.89	0.91	-0.78
Net Debt	0.5	0.41		0.34	0.36	0.57	0.24	-0.43	-0.21	0.06	0.55	-0.49	0.51	0.38	0.55	-0.03	-0.75	0.88	0.71	0.57	-0.66	0.3	0.13	0.33	-0.25
Retained Earnings	0.12	0.09	0.34		-0.07	0.14	0.01	-0.88	0.4	0.07	0.05	-0.18	0.14	-0.11	0.19	-0.08	-0.22	0.37	0.23	0.07	-0.09	-0.14	-0.18	-0.16	0.2
Accounts Payable	0.96	0.96	0.36	-0.07		0.94	0.96	-0.31	-0.41	0.63	0.97	0.27	0.92	0.96	0.59	0.7	-0.76	0.62	0.84	0.84	-0.77	0.89	0.94	0.94	-0.86
Total Liab	0.99	0.98	0.57	0.14	0.94		0.93	-0.47	-0.27	0.64	0.98	0.11	0.97	0.91	0.68	0.6	-0.84	0.83	0.93	0.89	-0.84	0.82	0.82	0.88	-0.76
Total Current Assets	0.96	0.98	0.24	0.01	0.96	0.93		-0.37	-0.24	0.75	0.93	0.37	0.93	0.92	0.58	0.73	-0.66	0.59	0.78	0.82	-0.7	0.86	0.93	0.91	-0.82
Common Stock	-0.46	-0.44	-0.43	-0.88	-0.31	-0.47	-0.37		-0.19	-0.38	-0.42	-0.01	-0.48	-0.31	-0.43	-0.15	0.43	-0.55	-0.48	-0.42	0.36	-0.25	-0.22	-0.26	0.22
Short Term Debt	-0.25	-0.22	-0.21	0.4	-0.41	-0.27	-0.24	-0.19		0.08	-0.37	0.09	-0.27	-0.41	-0.23	-0.23	0.35	-0.11	-0.3	-0.27	0.62	-0.4	-0.47	-0.43	0.36
Current Deferred Revenue	0.67	0.7	0.06	0.07	0.63	0.64	0.75	-0.38	0.08		0.62	0.31	0.67	0.62	0.39	0.56	-0.18	0.37	0.34	0.56	-0.39	0.57	0.69	0.61	-0.74
Net Receivables	0.98	0.96	0.55	0.05	0.97	0.98	0.93	-0.42	-0.37	0.62		0.13	0.96	0.94	0.66	0.63	-0.83	0.77	0.91	0.88	-0.83	0.85	0.87	0.92	-0.83
Net Tangible Assets	0.17	0.22	-0.49	-0.18	0.27	0.11	0.37	-0.01	0.09	0.31	0.13		0.24	0.32	0.07	0.2	0.07	-0.28	-0.02	0.21	0.07	0.31	0.37	0.34	-0.35
Long Term Debt	0.97	0.96	0.51	0.14	0.92	0.97	0.93	-0.48	-0.27	0.67	0.96	0.24		0.92	0.73	0.58	-0.77	0.78	0.88	0.89	-0.84	0.82	0.85	0.89	-0.75
Good Will	0.93	0.93	0.38	-0.11	0.96	0.91	0.92	-0.31	-0.41	0.62	0.94	0.32	0.92		0.57	0.63	-0.69	0.63	0.8	0.88	-0.73	0.91	0.92	1.0	-0.84
Long Term Debt Total	0.67	0.65	0.55	0.19	0.59	0.68	0.58	-0.43	-0.23	0.39	0.66	0.07	0.73	0.57		0.3	-0.66	0.71	0.69	0.76	-0.74	0.61	0.51	0.53	-0.44
Long Term Investments	0.65	0.69	-0.03	-0.08	0.7	0.6	0.73	-0.15	-0.23	0.56	0.63	0.2	0.58	0.63	0.3		-0.31	0.26	0.46	0.47	-0.39	0.64	0.75	0.62	-0.49
Treasury Stock	-0.8	-0.75	-0.75	-0.22	-0.76	-0.84	-0.66	0.43	0.35	-0.18	-0.83	0.07	-0.77	-0.69	-0.66	-0.31		-0.82	-0.97	-0.76	0.81	-0.62	-0.52	-0.64	0.54
Intangible Assets	0.78	0.73	0.88	0.37	0.62	0.83	0.59	-0.55	-0.11	0.37	0.77	-0.28	0.78	0.63	0.71	0.26	-0.82		0.86	0.81	-0.76	0.59	0.43	0.59	-0.42
Property Plant Equipment	0.91	0.87	0.71	0.23	0.84	0.93	0.78	-0.48	-0.3	0.34	0.91	-0.02	0.88	0.8	0.69	0.46	-0.97	0.86		0.82	-0.83	0.7	0.65	0.75	-0.58
Capital Surpluse	0.88	0.86	0.57	0.07	0.84	0.89	0.82	-0.42	-0.27	0.56	0.88	0.21	0.89	0.88	0.76	0.47	-0.76	0.81	0.82		-0.75	0.92	0.75	0.86	-0.73
Short Long Term Debt	-0.8	-0.76	-0.66	-0.09	-0.77	-0.84	-0.7	0.36	0.62	-0.39	-0.83	0.07	-0.84	-0.73	-0.74	-0.39	0.81	-0.76	-0.83	-0.75		-0.67	-0.69	-0.71	0.6
Net Invested Capital	0.84	0.85	0.3	-0.14	0.89	0.82	0.86	-0.25	-0.4	0.57	0.85	0.31	0.82	0.91	0.61	0.64	-0.62	0.59	0.7	0.92	-0.67		0.88	0.92	-0.78
Net Working Capital	0.86	0.89	0.13	-0.18	0.94	0.82	0.93	-0.22	-0.47	0.69	0.87	0.37	0.85	0.92	0.51	0.75	-0.52	0.43	0.65	0.75	-0.69	0.88		0.93	-0.84
Capital Stock	0.9	0.91	0.33	-0.16	0.94	0.88	0.91	-0.26	-0.43	0.61	0.92	0.34	0.89	1.0	0.53	0.62	-0.64	0.59	0.75	0.86	-0.71	0.92	0.93		-0.84
Accumulated Depreciation	-0.77	-0.78	-0.25	0.2	-0.86	-0.76	-0.82	0.22	0.36	-0.74	-0.83	-0.35	-0.75	-0.84	-0.44	-0.49	0.54	-0.42	-0.58	-0.73	0.6	-0.78	-0.84	-0.84

Click cells to compare fundamentals

About ANI Pharmaceuticals Financial Statements

ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	351.1 M	368.7 M
Gross Profit Margin	0.56	0.34

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC